Search
Bayer HealthCare Links
Company Brochure
Annual Report
Press portal
Clinical trials
Information about clinical studies is available at database of
HealthCare Links
News
-
2012-05-16 | Worldnews
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
2012-05-16 | Worldnews
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session more
-
2012-05-09 | Worldnews
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
2012-05-09 | Worldnews
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
Bayer’s cooperation partner, Janssen Research & Development, LLC has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration seeking approval for the use of Xarelto® (rivaroxaban) 2.5 mg BID to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS). more
-
2012-05-02 | Worldnews
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
2012-05-02 | Worldnews
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) more
-
2012-04-27 | Worldnews
Bayer has great potential for the future too
2012-04-27 | Worldnews
Bayer has great potential for the future too
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1 more
-
2012-04-26 | Worldnews
Encouraging start to the year for Bayer
2012-04-26 | Worldnews
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed more
Featured News in Social Media
-
Bayer promotes social projects in Germany: the winners of the Aspirin Social Award 2012Thu, May 10, 2012
at 5:05 pm
For three years now, the Bayer Cares Foundation has been supporting and honoring innovative, not-for-profit social projects in the health sector with the Aspirin Social Award. Every year applications are invited from support and counseling services from all over Germany that provide assistance in the health field in novel ways. Today was the presentation in Berlin of the Aspirin Social Award 2012, in which four of the 107 projects nominated won prizes.
» more -
How we work – Focus on Dissolution TestingWed, May 2, 2012
at 11:57 am -
Animal Health:
Which parasite do you see here?Wed, Apr 25, 2012
at 9:50 am - » more featured news
